SAN DIEGO, Dec. 9, 2015 /PRNewswire/ -- Nuklearmedizin, the German nuclear medicine journal, released new data today from a study that showed positron emission mammography (PEM) is capable of differentiating malignant breast tumors from benign lesions with a 100% sensitivity and 96% specificity when a threshold of PUVmax > 1.9 is applied. According to the publication, in this prospective single-site study 107 women and 1 man with clinical suspicious breast lesions were imaged. Each patient received 3.5 MBq of 18F-FDG per kg of body weight with PEM imaging done 90 minutes post-injection. A region of interest was used for analysis. Based on a criterion of maximum PEM uptake value (PUV) >1.9 being at high risk of being malignant, 31 out of 151 lesions in 108 patients were identified as possible cancers and biopsied, revealing 26 malignant lesions.
This study is the first to use the technology to both identify high risk lesions and then use the same device for biopsy guidance. This process could provide an efficient approach that is especially important for women who cannot tolerate a breast MRI.
"The results of this study demonstrate that PEM imaging is more accurate than mammography for both the identification and immediate sampling of suspicious breast lesions. This technology saves time and psychological worry for the patient and is a technology that physicians can easily use for problem solving when suspicious lesions are encountered," said Dr. Frank Muller MD PhD, Principal Investigator of the study.
Study can be found online at: http://nuk.schattauer.de/en/contents/archivestandard/issue/special/manuscript/25263.html and will be published in the January 2016 edition of Nuklearmedizin.
For further information about the study please contact Dr. Frank Muller at:
PEM scanners are high-resolution breast PET systems that can show both the location as well as the metabolic activity of a lesion. This information is critical, as this study showed, in identifying whether a lesion is malignant and provides a mechanism for easy sampling for histopathological analysis. This information is critical in determining the course of treatment for the patient.
About CMR Naviscan
CMR Naviscan is a leader in organ-specific molecular imaging and part of the Compania Mexicana de Radiologia CGR, S.A. de C.V. (CMR) family of companies. CMR is a major developer and manufacturer of high quality diagnostic imaging equipment that contributes to healthcare improvements through a technological innovation framework. This includes the conversion, storage, processing and distribution of diagnostic imaging in digital form. CMR Naviscan is headquartered in Carlsbad, California, is US FDA registered and ISO 13485:2012 certified. Our flagship product, the Solo II™ High Resolution Breast PET scanner, detects breast cancers as small as 1.6 mm. Solo II is the industry leader in terms of its sensitivity and specificity in characterizing the extent and location(s) of previously diagnosed breast cancers. For more information visit http://www.cmr-naviscan.com/.
SOURCE CMR Naviscan